ロード中...
2298. Infections in Patients Receiving TVEC Therapy
BACKGROUND: Oncolytic viral immunotherapy is an emerging cancer treatment, but the infectious complications are not well described outside of clinical trials. Genetically engineered replication competent herpes simplex virus (HSV-1), commercially known as IMLGYIC® (AmGen) or talimogene laherparepvec...
保存先:
| 出版年: | Open Forum Infect Dis |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6809872/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1976 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|